Global Diagnostic Antibodies Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diagnostic Antibodies Market Research Report 2024
Diagnostic Antibody detection is still the primary approach for confirmation of Lyme borreliosis. Quantitative EIAs (enzyme immune assays) are used as a first-line test with the possibility of supplementary western blotting (WB). Specific antibodies are detectable in serum and in CSF.
According to Mr Accuracy reports new survey, global Diagnostic Antibodies market is projected to reach US$ 38350 million in 2029, increasing from US$ 25970 million in 2022, with the CAGR of 6.0% during the period of 2024 to 2029.
The global diagnostic antibodies market refers to the market for antibodies used in diagnostic tests and assays for various diseases and conditions. Diagnostic antibodies play a crucial role in detecting and identifying specific biomarkers or targets in patient samples, aiding in the accurate diagnosis and monitoring of various diseases.
Key factors driving the growth of the global diagnostic antibodies market include
Increasing prevalence of chronic and infectious diseasesThe growing burden of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, has created a demand for accurate diagnostic tools. Diagnostic antibodies, with their high specificity and sensitivity, enable the detection of disease markers and facilitate early diagnosis and treatment.
Advancements in personalized medicineThe shift towards personalized medicine, where treatments are tailored to an individual’s specific characteristics and needs, has increased the demand for precise diagnostic tools. Diagnostic antibodies offer the ability to identify specific biomarkers associated with diseases, enabling personalized treatment strategies.
Technological advancements in antibody productionThe development of advanced techniques for antibody production, such as recombinant DNA technology and phage display technology, has revolutionized the diagnostic antibodies market. These technologies allow for the production of highly specific and reproducible antibodies, enhancing the accuracy of diagnostic tests.
Growing demand for point-of-care testingPoint-of-care testing (POCT) has gained significant popularity due to its convenience and rapid results. Diagnostic antibodies are essential components of many POCT devices, enabling on-site diagnosis and immediate treatment decisions.
Increasing healthcare expenditure and focus on early diagnosisWith rising healthcare expenditures and a growing emphasis on preventive healthcare, there is a greater focus on early disease detection. Diagnostic antibodies aid in the early diagnosis of diseases, enabling timely intervention and improved patient outcomes.
The global diagnostic antibodies market is highly competitive, with several key players dominating the market. These include Thermo Fisher Scientific, Abcam plc, Bio-Rad Laboratories, Inc., Merck KGaA, and Beckman Coulter, among others. These companies are actively engaged in research and development activities to develop innovative diagnostic antibodies and expand their product portfolios.
In summary, the global diagnostic antibodies market is driven by the increasing prevalence of chronic and infectious diseases, advancements in personalized medicine, technological advancements in antibody production, growing demand for point-of-care testing, and the focus on early diagnosis. The market is expected to witness further growth as the demand for accurate and reliable diagnostic tools continues to rise.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Aytu BioScience, Inc.
Agilent Technologies, Inc.
Abbott
Abcam plc.
Boehringer Ingelheim International GmbH
Bio-Rad Laboratories, Inc.
Roche Holding AG
Thermo Fisher Scientific
Merck KGaA
Beckman Coulter
Novus Biologicals
Cell Signaling Technology
Segment by Type
Monoclonal Antibodies
polyclonal Antibodies
Recombinant Polyclonal Antibodies
Others
Hospitals
Diagnostic Centre
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diagnostic Antibodies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Diagnostic Antibodies market is projected to reach US$ 38350 million in 2029, increasing from US$ 25970 million in 2022, with the CAGR of 6.0% during the period of 2024 to 2029.
The global diagnostic antibodies market refers to the market for antibodies used in diagnostic tests and assays for various diseases and conditions. Diagnostic antibodies play a crucial role in detecting and identifying specific biomarkers or targets in patient samples, aiding in the accurate diagnosis and monitoring of various diseases.
Key factors driving the growth of the global diagnostic antibodies market include
Increasing prevalence of chronic and infectious diseasesThe growing burden of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, has created a demand for accurate diagnostic tools. Diagnostic antibodies, with their high specificity and sensitivity, enable the detection of disease markers and facilitate early diagnosis and treatment.
Advancements in personalized medicineThe shift towards personalized medicine, where treatments are tailored to an individual’s specific characteristics and needs, has increased the demand for precise diagnostic tools. Diagnostic antibodies offer the ability to identify specific biomarkers associated with diseases, enabling personalized treatment strategies.
Technological advancements in antibody productionThe development of advanced techniques for antibody production, such as recombinant DNA technology and phage display technology, has revolutionized the diagnostic antibodies market. These technologies allow for the production of highly specific and reproducible antibodies, enhancing the accuracy of diagnostic tests.
Growing demand for point-of-care testingPoint-of-care testing (POCT) has gained significant popularity due to its convenience and rapid results. Diagnostic antibodies are essential components of many POCT devices, enabling on-site diagnosis and immediate treatment decisions.
Increasing healthcare expenditure and focus on early diagnosisWith rising healthcare expenditures and a growing emphasis on preventive healthcare, there is a greater focus on early disease detection. Diagnostic antibodies aid in the early diagnosis of diseases, enabling timely intervention and improved patient outcomes.
The global diagnostic antibodies market is highly competitive, with several key players dominating the market. These include Thermo Fisher Scientific, Abcam plc, Bio-Rad Laboratories, Inc., Merck KGaA, and Beckman Coulter, among others. These companies are actively engaged in research and development activities to develop innovative diagnostic antibodies and expand their product portfolios.
In summary, the global diagnostic antibodies market is driven by the increasing prevalence of chronic and infectious diseases, advancements in personalized medicine, technological advancements in antibody production, growing demand for point-of-care testing, and the focus on early diagnosis. The market is expected to witness further growth as the demand for accurate and reliable diagnostic tools continues to rise.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Aytu BioScience, Inc.
Agilent Technologies, Inc.
Abbott
Abcam plc.
Boehringer Ingelheim International GmbH
Bio-Rad Laboratories, Inc.
Roche Holding AG
Thermo Fisher Scientific
Merck KGaA
Beckman Coulter
Novus Biologicals
Cell Signaling Technology
Segment by Type
Monoclonal Antibodies
polyclonal Antibodies
Recombinant Polyclonal Antibodies
Others
Segment by Application
Hospitals
Diagnostic Centre
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diagnostic Antibodies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices